CJC-related product names can look deceptively similar. A catalog may contain CJC NO DAC, CJC W DAC, CJC+IPA, Ipamorelin, and Tesamorelin at the same time, yet those names do not describe interchangeable research materials. Some represent different growth-hormone-releasing-hormone analog structures, some are distinct secretagogues, and some are combination products whose labels need to be read component by component.
For researchers, laboratory purchasing teams, and documentation-focused readers, the useful question is therefore not simply “Which CJC product is this?” It is: what molecular identity does the name represent, what format is supplied, what does the lot documentation actually verify, and what experimental question is the material intended to support?
Affiliate disclosure: This post contains an affiliate link; the publisher may earn a commission from qualifying purchases.
Void Research materials discussed here are intended for controlled in-vitro/laboratory research by qualified researchers. They are not intended for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, supplements, cosmetics, or personal experimentation.
Researchers comparing the current catalog can start with the Void Research BOOST30 research-product destination. The campaign code is BOOST30, with up to 30% off.
This article focuses on how to distinguish CJC variants and related catalog entries, especially CJC NO DAC, CJC W DAC, CJC+IPA, Ipamorelin, and Tesamorelin, while keeping molecular identity, evidence, product format, and certificate-of-analysis documentation separate.
The shortest answer: these names should not be treated as synonyms
The most important distinction can be stated simply.
CJC NO DAC refers to a short-acting modified GHRH fragment without the Drug Affinity Complex modification associated with long-acting CJC-1295.
CJC W DAC refers to a long-acting CJC-1295-type material incorporating the modification that supports extended albumin association.
CJC+IPA is a combination listing involving a CJC component and Ipamorelin rather than one newly defined peptide.
Ipamorelin is a separate growth-hormone secretagogue peptide and should not be described as a CJC variant.
Tesamorelin is another GHRH-related peptide, but it has its own molecular identity, development history, regulatory context, and human clinical evidence. It should not be collapsed into the CJC naming family merely because both are discussed in growth-hormone-axis research.
Those distinctions matter because a laboratory can make a serious sourcing or interpretation error if it treats a familiar shorthand as a complete chemical description.
A useful research record should therefore preserve at least four separate fields:
catalog name → actual molecular identity → supplied format → lot-specific documentation
If one of those fields is unclear, the material should not be characterized merely from the commercial title.
Why CJC terminology creates confusion
CJC terminology sits at an awkward intersection of formal scientific names, historical development names, vendor shorthand, and informal research-community vocabulary.
The best-known scientific literature on CJC-1295 concerns a long-acting growth-hormone-releasing-hormone analog. A 2006 randomized study by Teichman and colleagues described CJC-1295 as a long-acting GHRH analog and reported prolonged pharmacodynamic activity in healthy adult research participants. A related publication examined persistence of pulsatile GH secretion during continuous stimulation and described the albumin-binding characteristic associated with the long-acting molecule.
That literature is important, but it creates a naming trap.
A current supplier listing labeled CJC NO DAC should not automatically be assumed to be identical to the long-acting CJC-1295 material evaluated in those publications. The absence of the DAC-related modification is precisely the feature that distinguishes the “NO DAC” label from the long-acting form.
In practical documentation work, that means a researcher should not cite a long-acting CJC-1295 paper merely because a product title contains “CJC.”
The publication must first be matched to the identity of the material under discussion.
For a complementary overview of the naming issue, the previously published guide on CJC NO DAC vs CJC W DAC vs CJC+IPA research distinctions provides additional catalog-level context.
CJC NO DAC: what the name is trying to communicate
In the current Void Research catalog, CJC NO DAC is presented as a separate research product rather than as a formatting option under CJC W DAC.
The product information identifies it with Modified GRF (1-29) / CJC-1295 no DAC terminology and characterizes it as a 29-amino-acid GHRH analog without the Drug Affinity Complex modification.
The phrase “no DAC” therefore matters chemically, not just commercially.
The purpose of the label is to distinguish a modified GHRH fragment that lacks the long-acting albumin-binding design associated with CJC-1295 DAC.
For documentation purposes, that distinction should be retained exactly.
A laboratory record should not silently shorten:
CJC-1295 no DAC / Modified GRF (1-29)
to:
CJC-1295
if doing so could make the material appear equivalent to the long-acting form.
Why the “Modified GRF (1-29)” wording matters
Growth-hormone-releasing hormone is a larger peptide, but the biologically relevant N-terminal region led to research into shorter analogs and modified fragments.
Modified GRF (1-29) terminology points toward that shorter analog lineage.
Researchers reading older literature may encounter several related labels, including GHRH fragments, modified GRF terminology, CJC terminology, and vendor-specific abbreviations. The correct response is not to assume they are interchangeable but to trace the actual sequence or structural description where available.
This is one reason a product name is only the first documentation layer.
The next layers should include, where available:
- sequence or structural description;
- molecular weight;
- CAS number;
- formulation or lyophilized format;
- nominal content;
- lot number;
- identity-testing result;
- purity-testing result;
- quantitative content result;
- and source laboratory information.
CJC W DAC: the long-acting naming branch
CJC W DAC should be treated as a separate material from CJC NO DAC.
The “W DAC” wording refers to the Drug Affinity Complex-related design associated with prolonged binding to circulating albumin.
That modification is central to the pharmacokinetic concept behind the original CJC-1295 development program.
In the 2006 Teichman study, the tested long-acting CJC-1295 analog produced prolonged changes in measured GH and IGF-I parameters. A subsequent publication examined GH pulsatility after exposure to the long-acting analog.
These human studies are useful when describing the scientific history of long-acting CJC-1295.
They do not mean that every commercial material containing “CJC” has the same identity, pharmacokinetics, quality, or evidentiary support.
What researchers should record
If a laboratory acquires a material labeled CJC W DAC, the internal record should preserve the complete label.
A useful entry might contain fields such as:
Catalog identity: CJC W DAC
Research family: GHRH analog
Declared format: supplier-specific vial format
Declared content: according to current product page and label
Lot number: exact lot from vial
COA: matched to the same lot
Identity result: as reported by the testing laboratory
Purity result: as reported by the testing laboratory
Content/quantity result: where independently reported
Date tested: from the applicable certificate
The point is traceability.
If a later investigator reviews experimental records, they should be able to determine which CJC form was actually used without having to reconstruct the answer from an abbreviated note.
CJC NO DAC versus CJC W DAC is not merely a duration comparison
It is tempting to describe these two names using only “short acting” and “long acting.”
That shorthand is useful as an orientation, but it is incomplete.
The deeper difference is structural.
The presence or absence of the albumin-binding modification changes what molecule is being discussed and which published evidence is directly relevant.
Therefore, researchers should compare:
identity first, pharmacology second.
The wrong sequence is:
both affect the same biological axis, therefore they are basically the same compound.
The better sequence is:
these compounds are related through GHRH biology, but structural differences can alter pharmacokinetic behavior, literature relevance, analytical characterization, and experimental interpretation.
This distinction becomes especially important when designing comparative research.
If the scientific question involves persistence of signaling, kinetics, receptor activation over time, or downstream biomarker timing, material identity may be an experimental variable in its own right.
Where CJC+IPA fits
CJC+IPA introduces another naming problem because it is a combination product, not simply another CJC derivative.
In the Void Research catalog, CJC+IPA is presented as a product containing a CJC-related component together with Ipamorelin.
That means its label needs to be interpreted at component level.
Researchers should ask:
- Which specific CJC form is included?
- How much of each component is declared?
- Is the displayed quantity a combined total or a per-component quantity?
- Does the COA characterize the mixture appropriately?
- Can the analytical method distinguish the declared components?
- Does the research design actually call for a mixture rather than isolated compounds?
A previously published catalog guide notes an example in which the CJC+IPA listing was described as a 10 mg total combination containing 5 mg of CJC-related material and 5 mg of Ipamorelin. That illustrates why the headline number on a blend should not be read as though it represents the full amount of each constituent.
A mixture and an individual compound answer different research questions
Suppose a project aims to characterize a mixture as supplied.
A combination material may be appropriate because the mixture itself is the analytical object.
Now suppose the project aims to determine whether one component contributes differently from another.
A premixed material alone cannot answer that question as cleanly.
The study would normally require appropriate controls and individually characterized materials if the objective is to separate component-specific effects.
That is not unique to peptides. It is a basic experimental-design issue.
A blend can be a legitimate research object without becoming a substitute for each constituent.
Ipamorelin is not a CJC variant
Ipamorelin frequently appears beside CJC-related products because both are discussed within growth-hormone-axis research, but their mechanisms and molecular classifications differ.
Ipamorelin was described in the scientific literature as a selective growth-hormone secretagogue.
The often-cited 1998 paper by Raun and colleagues characterized Ipamorelin as a pentapeptide growth-hormone secretagogue and investigated its pharmacology in laboratory and animal models.
That is a different research lineage from the GHRH-analog lineage of CJC compounds.
Put simply:
CJC-type compounds are discussed as GHRH analogs.
Ipamorelin is discussed as a growth-hormone secretagogue acting through the GHRP/ghrelin-receptor pathway.
Those are related endocrine research areas, but they are not the same molecular mechanism.
The distinction is useful because the phrase “CJC IPA” can visually blur two names into one.
Researchers should mentally expand it:
CJC component + Ipamorelin component.
For a focused comparison, see the previously published discussion of Ipamorelin and Tesamorelin as distinct research entities.
Why the Ipamorelin COA is more informative than a catalog title
The current Void Research Ipamorelin product page provides a good example of lot-specific documentation.
At the time this article was checked, the page displayed a current lot certificate containing information including:
- the labeled amount;
- measured content;
- HPLC purity;
- identity confirmation;
- endotoxin testing;
- testing date;
- batch identifier;
- COA number;
- and laboratory verification information.
That is substantially more useful for procurement records than a statement such as “Ipamorelin 10 mg.”
The catalog title describes what the product is supposed to be.
The COA describes what was measured for a specific tested lot.
Those are different claims.
Identity and purity answer different questions
This distinction deserves emphasis.
Identity testing asks whether the material corresponds to the expected compound.
Purity testing examines the proportion of the analyzed material represented by the main target peak or otherwise reports purity according to the analytical method.
Neither measurement automatically answers:
How much material is actually in the vial?
That requires an appropriate quantitative content or assay measurement.
Likewise, a measured content result does not by itself establish chemical identity.
A strong documentation package therefore separates these concepts rather than compressing them into one headline percentage.
Tesamorelin is related through GHRH biology but has a very different evidence history
Tesamorelin is particularly important to distinguish from experimental CJC catalog terminology because it has a more developed human clinical and regulatory history.
Tesamorelin is a synthetic growth-hormone-releasing-factor analog.
Published randomized controlled studies evaluated tesamorelin in people with HIV-associated abdominal fat accumulation. For example, a large study involving hundreds of participants examined visceral adipose tissue and other endpoints over sequential treatment phases. Additional randomized research examined visceral and liver fat.
Those studies represent human clinical evidence for tesamorelin in specific investigated populations and contexts.
They do not establish equivalent clinical evidence for CJC NO DAC, CJC W DAC, CJC+IPA, or Ipamorelin.
That distinction is essential when building evidence tables.
The presence of all five names in a single supplier catalog should never flatten their evidence hierarchies.
Avoid “same pathway, same evidence”
Two research materials can influence related pathways yet have very different evidence bases.
Tesamorelin illustrates this clearly.
Its published human studies should be attributed to Tesamorelin.
They should not be generalized to another GHRH analog simply because that compound also interacts with the GH/IGF-I axis.
Likewise, results from CJC-1295 studies should remain attached to the CJC-1295 material actually studied.
For a longer evidence-focused comparison, the existing article on the evidence hierarchy for CJC, Ipamorelin, and Tesamorelin research provides a useful companion reference.
A practical comparison of the five catalog names
| Catalog name | What it represents | Core distinction | Documentation priority |
|---|---|---|---|
| CJC NO DAC | Modified GHRH-related peptide without DAC | Shorter-acting/non-DAC research identity | Confirm exact molecular identity, lot, purity, identity and content |
| CJC W DAC | Long-acting CJC-1295-type material with DAC-related modification | Albumin-binding design and longer pharmacokinetic profile | Confirm DAC form, lot-specific analytical data and identity |
| CJC+IPA | Combination material | CJC component plus Ipamorelin component | Verify each component, declared ratio/quantity and mixture documentation |
| Ipamorelin | Growth-hormone secretagogue pentapeptide | Separate GHRP/ghrelin-receptor research mechanism | Verify identity, purity, content, lot and relevant assay results |
| Tesamorelin | GHRH/GRF analog | Distinct compound with human clinical development history | Keep clinical evidence specific to Tesamorelin and verify research-product lot separately |
This table is an orientation tool, not a substitute for the original product page, scientific literature, or certificate.
Product names should be separated from evidence labels
A common documentation error is to copy a commercial product name into a research report and allow that name to stand in for the entire scientific identity.
A better system separates three layers.
Layer 1: supplier catalog identity
This is exactly what the product page calls the material.
Examples:
- CJC NO DAC
- CJC W DAC
- CJC+IPA
- IPAMORELIN
- TESAMORELIN
Do not “correct” these names inside the procurement record unless a separate standardized-name field is available.
Layer 2: scientific identity or research classification
This describes the material more formally.
For example:
- modified GHRH analog;
- long-acting CJC-1295-type analog;
- combination product;
- growth-hormone secretagogue;
- or GHRH/GRF analog.
This field helps connect a catalog item to the scientific literature without pretending that commercial shorthand is a universal nomenclature standard.
Layer 3: evidence source
This identifies what publication or database actually supports the statement being made.
A claim about long-acting CJC-1295 pharmacokinetics should cite long-acting CJC-1295 research.
A claim about Ipamorelin receptor pharmacology should cite Ipamorelin research.
A clinical result involving Tesamorelin should cite Tesamorelin research.
Maintaining this separation sharply reduces accidental overgeneralization.
How to read a COA for these products
A certificate of analysis is one of the most useful documents in peptide procurement, but it should be read field by field rather than treated as a generic quality badge.
Product name
Confirm that the certificate names the same material as the vial or product record.
Similar-looking names are not sufficient.
A certificate for CJC W DAC should not be filed as documentation for CJC NO DAC.
Lot or batch number
This is one of the most important fields.
The lot on the physical product should correspond to the lot on the certificate.
A valid certificate for a different batch provides historical information, but it is not lot-specific evidence for the material in hand.
Test date
Testing dates help establish whether the document corresponds to the current production batch and can help with audit chronology.
Identity
Identity testing supports the question:
Is the detected material consistent with the expected compound?
Researchers should note the method used rather than relying only on the word “confirmed.”
Purity
HPLC purity commonly appears in research-peptide documentation.
A high HPLC percentage can be useful information, but it should not be interpreted as proof of every quality characteristic.
Purity does not by itself establish identity, exact vial content, sterility, experimental suitability, or biological activity.
Quantitative content
If the certificate reports measured content, compare it with the labeled amount.
This is a different measurement from chromatographic purity.
For example, a vial could theoretically show a very high purity percentage for the main detected species while still containing a different total amount than the label states. That is why purity and content should be recorded independently.
Additional analytical fields
Depending on the lot and supplier documentation, a certificate may include other assays such as endotoxin-related testing or additional analytical checks.
The significance of each field depends on the experimental context.
Researchers should avoid turning the mere number of assays into a universal ranking system.
Eight tests are not automatically “better” than four unless the additional tests are relevant, methodologically sound, and interpreted correctly.
COA documentation does not prove experimental performance
This point is particularly important in commercial peptide discussions.
A certificate can provide evidence about an analyzed sample.
It cannot tell a researcher that a material will produce a specific biological result in a particular model.
Experimental outcomes depend on factors such as:
- model system;
- receptor expression;
- sample preparation;
- assay sensitivity;
- incubation conditions;
- controls;
- timing;
- analytical methodology;
- and statistical design.
Supplier documentation and scientific literature therefore answer different questions.
A COA addresses characteristics of the supplied material.
A peer-reviewed experiment addresses a research question under defined conditions.
Neither should be used as a substitute for the other.
Why product format matters
The current Void Research storefront separates multiple types of products, including peptides, sprays, and supplies.
Format should be recorded because two products sharing a related active compound name may still differ in presentation, composition, concentration, excipients, packaging, or intended laboratory handling.
The presence of a spray listing does not make the material medically appropriate or imply anything about human administration.
For a research-only catalog, format is primarily a procurement and experimental-design attribute.
A useful inventory record may therefore include:
- material name;
- catalog category;
- physical format;
- labeled quantity;
- blend composition if applicable;
- lot;
- date received;
- storage condition;
- COA location;
- analytical laboratory;
- and research-use restriction.
For additional discussion of CJC terminology without collapsing the different materials into one category, see the earlier CJC naming and research-context explainer.
Why “companion products” does not mean interchangeable products
CJC, Ipamorelin, and Tesamorelin may appear in the same research conversation because they intersect with the GH/IGF-I axis.
However, grouping them for discussion should not erase their separate molecular identities.
A good analogy is a pathway map.
Several compounds may influence neighboring nodes in the same biological network, but the fact that their downstream measurements overlap does not make them chemically equivalent.
This is particularly relevant when researchers read phrases such as:
- “frequently researched together”;
- “companion compound”;
- “related secretagogue”;
- or “same research category.”
Those phrases describe catalog proximity or biological context.
They are not evidence of equivalence.
Evidence hierarchy: separate discovery research from clinical evidence
A responsible literature review should mark the type of evidence associated with every claim.
In-vitro research
Cell-based experiments can reveal receptor interactions, potency relationships, signaling mechanisms, or analytical characteristics.
They do not directly establish outcomes in whole organisms.
Animal research
Animal models add pharmacodynamic and physiological information but still require caution when extrapolating between species.
The original Ipamorelin literature, for example, includes extensive preclinical pharmacology.
That evidence should be described as preclinical where appropriate.
Human experimental research
Long-acting CJC-1295 was investigated in controlled human studies examining pharmacokinetic and endocrine outcomes.
Those findings apply to the studied molecule and protocol.
Human clinical trials
Tesamorelin has randomized controlled clinical research in specific HIV-associated adiposity populations.
Again, those results belong to Tesamorelin in the population and conditions studied.
Supplier testing
A supplier COA is analytical documentation, not a clinical trial and not a biological efficacy experiment.
Keeping those categories separate prevents one of the most common errors in peptide content: moving a finding from one evidence level into another without justification.
How a procurement team can compare the listings without overcomplicating the process
A practical laboratory review does not need to become a regulatory dossier.
A short sequence works well.
First, record the exact product name.
Second, determine whether it is a single compound or combination.
Third, identify the scientific identity or compound family.
Fourth, open the lot-specific certificate.
Fifth, match the lot number.
Sixth, read identity, purity, quantitative content, and other relevant assays separately.
Seventh, check whether the cited scientific evidence actually involves the same material.
Eighth, retain the product page and certificate with the purchasing record.
Ninth, confirm that the material is suitable for the institution's approved research and legal framework.
Finally, evaluate commercial terms only after the scientific and documentation requirements are satisfied.
That sequence helps keep price from becoming the primary quality signal.
A note on BOOST30 and purchasing economics
For qualified research procurement readers who have already determined that a product and its documentation fit their laboratory requirements, Void Research's campaign code is BOOST30, described as up to 30% off.
The discount should remain secondary to the technical review.
A lower purchase price does not change the identity of a compound, improve an analytical method, strengthen an evidence base, or make an unsuitable material appropriate for an experiment.
The useful purchasing sequence is:
identify the required material → verify documentation → check lot information → review procurement terms → apply the available commercial offer.
That keeps scientific suitability separate from commercial incentive.
Shipping and international procurement
Shipping availability should not be interpreted as proof that a research material can legally be imported, possessed, or used in every jurisdiction.
For international orders where service is available and permitted by law, the receiving researcher or institution remains responsible for destination-country requirements.
Depending on the jurisdiction and shipment, issues can include:
- customs classification;
- importer-of-record responsibilities;
- duties;
- VAT or GST;
- import documentation;
- customs delays;
- seizure risk;
- institutional purchasing restrictions;
- and local laws governing possession or research use.
A commercial checkout system accepting an address is not equivalent to legal authorization.
Professional procurement teams should review their own requirements before ordering.
Frequently asked questions
Is CJC NO DAC the same as CJC-1295 with DAC?
No. The “NO DAC” designation specifically indicates the absence of the modification associated with the long-acting form. Researchers should preserve the distinction in records and literature matching.
Is CJC W DAC the same as CJC NO DAC with a different vial size?
No. The distinction refers to molecular design, not merely package size.
Is CJC+IPA one peptide?
It should be treated as a combination product containing a CJC-related component and Ipamorelin. Researchers should verify the exact declared composition and how the total labeled quantity is divided between components.
Is Ipamorelin a type of CJC?
No. Ipamorelin is a distinct growth-hormone secretagogue peptide with a different pharmacological lineage.
Is Tesamorelin another name for CJC?
No. Tesamorelin is a distinct GHRH/GRF analog with its own molecular identity and clinical research history.
Why are all of these products discussed together?
They can intersect in research concerning the growth-hormone/IGF-I axis, but pathway proximity does not make them chemically or evidentially equivalent.
What should be checked first on a peptide COA?
Start by matching the product identity and lot number. Then evaluate the analytical fields individually, including identity, purity, measured content where available, testing date, methods, and laboratory information.
Does 99% HPLC purity mean 99% of the labeled amount is in the vial?
Not necessarily. HPLC purity and quantitative content are different measurements. Researchers should not substitute one for the other.
Does a COA prove biological effectiveness?
No. It reports analytical characteristics of a tested sample. Biological performance requires experimental evidence appropriate to the model and research question.
Can a certificate from one lot be used for another lot?
It can provide historical context about a supplier's testing, but it is not lot-specific evidence for a different batch. Match the actual lot whenever possible.
Should a researcher choose CJC+IPA instead of separate CJC and Ipamorelin materials?
That depends entirely on the research question. A blend may be relevant when the mixture itself is being studied. Separate materials are generally more informative when the goal is to distinguish component-specific observations.
Does published Tesamorelin clinical evidence apply to CJC NO DAC?
No. Clinical findings for one compound should not automatically be transferred to another related compound.
What is the Void Research promo code covered here?
The campaign code is BOOST30, with up to 30% off.
Are these products intended for personal use?
No. The research materials discussed in this article are for controlled laboratory/in-vitro research by qualified researchers and are not for human or veterinary administration, consumption, diagnosis, treatment, or personal experimentation.
Final perspective: start with identity, not the abbreviation
CJC-related nomenclature becomes much easier to understand once the catalog is separated into actual research entities.
CJC NO DAC is not simply an informal spelling of CJC W DAC.
CJC+IPA is not a third isolated CJC molecule; it is a combination whose components need to be documented separately.
Ipamorelin is not a CJC derivative simply because it is often discussed alongside CJC-related materials.
Tesamorelin is not interchangeable with CJC terminology merely because both sit within GHRH-related research.
And no catalog label, however familiar, should replace lot-level analytical documentation.
For researchers and procurement teams, the most defensible workflow is straightforward:
record the exact name, establish the actual identity, distinguish single compounds from blends, match the correct evidence, verify the lot certificate, and keep commercial considerations separate from scientific suitability.
For qualified laboratory procurement after those checks are complete, the Void Research BOOST30 affiliate destination provides access to the current catalog. Use promo code BOOST30 for up to 30% off.
All products discussed here remain strictly for controlled in-vitro/laboratory research by qualified researchers and are not for human or veterinary use, consumption, administration, clinical application, diagnosis, treatment, cure, prevention, or personal experimentation.
Top comments (0)